



1/39

Fig.1a.

Peptide pool 3




Gliadin digest



2/39

Fig.1b.



3/39

Fig.2a.






Fig.2b.



4/39



5/39

Fig.4a.





Fig.4b.



6/39

Fig.5.





Fig.6.



7/39

Fig.7a.





Fig.7b.



8/39







Fig.9.



10/39


Fig.10.



11/39

Fig. 11.

Peptide length and bioactivity: Means (n=4)
A-gliadin 57-73 QE65 (17aa)=100%



12/39

Fig.12a.

Dose response to A-gliadin 57-73 QE65:
QLQPFQPELPYPQPQS.





Fig.12b.

Dose response to GDA4_WHEAT P04724 84-100 QE92:
PQLPYPQPELPYPQPQP.



13/39

Fig.12c.

Dose response to A-gliadin 57-73:
QLQPFQPQLPYQPQS (2.5, 25 & 250 mcg/ml),
and A-gliadin 57-73 (25 mcg/ml) + tTG treatment.





Fig.12d.


Dose response to GDA4_WHEAT P04724 84-100:
PQLPYQPQLPYQPQP (2.5, 25 & 250 mcg/ml),
and P04724 84-100 (25 mcg/ml) + tTG treatment.



14/39

Fig.12e.


Dose response to the DQ2-restricted α gliadin T cell epitope A-gliadin 57-68 QE65: QLQPFPPQPELPY (E65) (2.5, 25 & 250 mcg/ml), and A-gliadin 57-68: QLQPFPPQPQLPY (Q65) (25 mcg/ml) +/- tTG treatment.



15/39

Fig.12f.


Dose response to the DQ2-restricted α gliadin T cell epitope α -2 62-75 QE65 & QE72: PQPELPYPQPELPY (E65) (2.5, 25 & 250 mcg/ml), and α -2 62-75: PQQQLPYPQQQLPY (Q65) (25 mcg/ml) +/- tTG treatment.



16/39

Fig.12g.


Dose response to the DQ8-restricted α gliadin T cell epitope GDA9 202-219: QE208 & 216: QQYPSGEGSFQPSQENPQ (E) (25 & 250 mcg/ml), and to GDA9 202-219 QQYPSGQGSFQPSQQNPQ (Q) (25 mcg/ml) +/- tTG treatment.



17/39

Fig. 12h.

Dose response to the DQ2-restricted γ gliadin T cell epitope GDB2 134-153 QE140, 148, 150: QQLPQPEQPQQSFPEQERPF (E) (25 & 250 mcg/ml), and to GDB2 134-153: QQLPQPQQPQQSFPPQQRP (Q) (25 mcg/ml) +/- tTG treatment.



18/39

Fig.13a.

Dose response to gliadin digest by
chymotrysin.





Fig.13b.

Dose response to gliadin digested by
chymotrysin then treated with tTG.




19/39

Fig.13c.

Total ELISpot responses to A-gliadin 57-73 QE65 (25mcg/ml) versus A-gliadin 57-73 QE65 responses as percent of tTG gliadin (500mcg/ml) responses.

Responses to dominant epitope and complete antigen (A-gliadin 57-73 QE65 and tTG-treated gliadin)




20/39

(Fig.14.)

Bioactivity of gliadin polymorphisms of A-gliadin 57-73
(A) in coeliac subjects 6/7 days after gluten challenge
(Gamma-Interferon Elispot) (n=4).


Fig.14a.



A	QLQPFPPQPQLPYPQPQS	I	QLQPFPPQPQLSYSQPQP
B	QLQPFPPQPQLPYPQPQP	J	QPQPFPPPQLPYPQTQP
C	QLQPFPPQPQLPYPQPQL	K	PQLPYPQPQLPYPQPQP
D	QLQPFPPQPQLPYLQPQS	L	PQLPYYPQPQLPYPQPQL
E	QLQPFPPRPQLPYPQPQP	M	PQPQPFLPQLPYPQPQS
F	QLQPFPPQPQLPYSQPQP	N	PQPQPFPPQLPYPQPQS
G	QLQPFLLQPQLPYSQPQP	O	PQPQPFPPQLPYPQTQP
H	QLQPFSSQPQLPYSQPQP	P	PQPQPFPPQLPYPQPPP

21/39

Fig.14b.




A QLQPFPPQPQLPYPQPQS
 B QLQPFPPQPQLPYPQPQP
 C QLQPFPPQPQLPYPQPQL
 D QLQPFPPQPQLPYLQPQS
 E QLQPFPPQPQLPYPQPQP
 F QLQPFPPQPQLPYSQPQP
 G QLQPFLLQPQLPYSQPQP
 H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP
 J QPQPFPPPPQLPYPQTQP
 K PQLPYPQPQLPYPQPQP
 L PQLPYPQPQLPYPQPQL
 M PQPQPFLPQLPYPQPQS
 N PQPQPFPPQLPYPQPQS
 O PQPQPFPPQLPYPQTQP
 P PQPQPFPPQLPYPQPPP

22/39

Fig.14c.



A	QLQPFFPQPQLPYPQPQS	I	QLQPFFPQPQLSYSQPQP
B	QLQPFFPQPQLPYPQPQP	J	QPQPFFPPQLPYPQTQP
C	QLQPFFPQPQLPYPQPQL	K	PQLPYPQPQLPYPQPQP
D	QLQPFFPQPQLPYLQPQS	L	PQLPYPQPQLPYPQPQL
E	QLQPFFPRPQLPYPQPQP	M	PQPQFPLPQLPYPQPQS
F	QLQPFFPQPQLPYSQPQP	N	PQPQFPPQLPYPQPQS
G	QLQPFLQPQLPYSQPQP	O	PQPQFPPQLPYPQTQP
H	QLQPFSQPQLPYSQPQP	P	PQPQFPPQLPYPQPPP

23/39

Fig.14d. QE65-substituted (2.5 mcg/ml): Means (error bars: 1 SEM)





Fig.14e. QE65-substituted (250 mcg/ml): Means (error bars: 1 SEM)



A	QLQPFPPQPQLPYQPQS	I	QLQPFPPQPQLSYSQPQP
B	QLQPFPPQPQLPYQPQP	J	QPQPFPPQPQLPYPQTQP
C	QLQPFPPQPQLPYQPQL	K	PQLPYQPQLPYQPQP
D	QLQPFPPQPQLPYLQPQS	L	PQLPYQPQLPYQPQL
E	QLQPFPPRPQLPYQPQP	M	PQPQFLLPQLPYQPQS
F	QLQPFPPQPQLPYSQPQP	N	PQPQFPPQPQLPYQPQS
G	QLQPFLLQPQLPYSQPQP	O	PQPQFPPQPQLPYPQTQP
H	QLQPFSSQPQLPYSQPQP	P	PQPQFPPQPQLPYQPQP

24/39

Fig.15.

Alanine scan: Means (error bars: 95% CI for mean)





Fig.16.

Lysine scan: Means (error bars: 95% CI for mean)




25/39

Fig.17.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




26/39

Fig.18.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPELPYPQPQS

60.....70




27/39

Fig.19.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPEL⁶¹PYP⁶²QPQS

60.....70




28/39

Fig.20.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPELPYPQPQS

60.....70




29/39

Fig.21.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




30/39

Fig.22.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰QPELPYPQ⁷⁰QS

60.....70




31/39

Fig.23.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPELPYPQPQS⁷⁰

60.....70




32/39

Fig.24.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPELPYPQPQS⁷⁰

60.....70



33/39

Fig.25.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰PQPELPYPQPQS

60.....70





Fig.26.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF⁶⁰FPQPELPYPQPQS

60.....70




35/39

Fig.27.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




36/39

(Fig.28.)

Interferon gamma ELISpot responses in newly diagnosed and treated coeliac subjects, before and after gluten challenge.

Fig.28a. Untreated, newly diagnosed coeliacs (Mean+SEM, n=9)



37/39

Fig.28b.





Fig.28c.



38/39

Fig.28d.




Fig.28e.




Fig.28f.

2 months GFD (Mean+SEM,n=3)




Fig.28g.

Day 6 gluten challenge after 2 mo GFD (Mean+SEM,n=3)

